Harvard Bioscience, Inc.
corporate_fare Company Profile
Harvard Bioscience, Inc. (NASDAQ:HBIO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 24 items for HBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-11, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for HBIO spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Harvard Bioscience Lifts Full-Year Outlook as Q2 Revenue Climbs 11%
- Harvard Bioscience lifts full-year outlook as Q2 revenue climbs 11%
- Stockholders Approve Plans Authorizing 1.99M New Shares, Potential 44% Dilution
- Harvard Bioscience Alleviates Going Concern, Regains Nasdaq Compliance, Reports Reduced Q1 Loss
- Harvard Bioscience Updates Investors on Q1 Results, Debt Refinancing, and Strategic Consolidation
Financial Snapshot
Short Interest & Short Volume
2.59 days to coverFINRA reported short interest of 48,146 shares in HBIO as of the September 15, 2026 settlement, a 0.8% decrease from the prior period — about 2.6 days to cover at its recent average daily volume. On October 7, 2026, 42.0% of HBIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.